Panic Disorder Market with Future Growth Opportunity by Top...

Panic Disorder Market with Future Growth Opportunity by Top Companies to 2030

Posted 2023-12-07 06:58:51

Market Dynamics The global market for treating panic disorder is poised to demonstrate a consistent revenue Compound Annual Growth Rate (CAGR) throughout the forecast period. The upsurge in mental disorders and anxiety disorders' prevalence is propelling revenue growth in this market. However, the variation in patient responses to treatment and a lack of awareness among the population are leading to a dearth of specific treatments, which is impeding the revenue growth of the panic disorder treatment market. Additionally, the COVID-19 pandemic contributed to revenue growth as the number of psychiatric patients increased during this period.

Major Companies in the Market Include:

Teva Pharmaceutical Industries Ltd.
Bristol-Myers Squibb Company
Noven Pharmaceuticals
Eli Lilly & Company
Sumitomo Dainippon Pharma Co.
SHIONOGI & Co.
Baxter
GlaxoSmithKline plc.
Pfizer Inc.
Recordati Rare Diseases, Ltd.
Boehringer Ingelheim International GmbH.
Bausch Health Companies Inc.
Sun Pharmaceutical Industries Ltd.
Mylan N.V.

What Our Report Provides and Why Our Offering Is Superior: This report provides historical data, forecasts, and revenue growth at the global, regional, and country levels. It offers an analysis of industry trends, consumption patterns, and market strategies for each region, major country, and segment from 2019 to 2030. The report includes insights on industry trends, drivers, restraints, opportunities, threats, segment revenue, and the revenue share contribution of each regional and country market. Additionally, the report provides industry analysis, a competitive landscape, company financials, and impact analysis.

Panic disorder is a mental and behavioral condition characterized by recurrent and spontaneous panic attacks. These sudden and intense episodes of fear can involve symptoms such as palpitations, sweating, shaking, shortness of breath, numbness, and a sense of impending doom. These sensations reach their peak within minutes. Individuals with panic disorder often worry about experiencing further attacks and may avoid places where previous episodes occurred. It is considered an anxiety disorder, with risk factors including smoking, emotional stress, and a history of childhood maltreatment.

Get a sample copy of the Panic Disorder Market report: https://www.reportsanddata.com/download-free-sample/5166

Factors Supporting Revenue Growth

Drivers Several factors are driving the revenue growth of the panic disorder market. According to the National Institute of Mental Health (NIMH), the prevalence of anxiety disorders varies with age. Anxiety disorders affect 22.3% of individuals aged 18 to 29, 22.7% of those aged 30 to 44, and 20.6% of those aged 45 to 59. It is less common among those aged 60 or older, with only 9% experiencing anxiety. Panic disorders affect 2.7% of the population, with 3.8% of women and 1.6% of men affected. An increase in panic disorder diagnoses, particularly due to rising mental health issues, is contributing to revenue growth. In the United States, data from the National Comorbidity Survey Adolescent Supplement (NCS-A) suggests that 2.3% of teenagers aged 13 to 18 had severe impairment and 2.3% had panic disorder. The market is also growing due to an increase in clinical trials by pharmaceutical companies and the rising demand for specific treatments to address complications associated with panic disorder.

Opportunities A rise in research and development activities in pharmaceuticals for symptomatic and targeted treatments of panic disorder is driving revenue growth. Each type of panic disorder is associated with specific gene variations, enabling the development of targeted and effective genetic therapies. Raising awareness among the population can be an opportunity for scientists and innovators to develop effective medications for panic disorder patients, thereby sustaining revenue growth.

Geographic Market Scenario

Largest Market Share North America is expected to dominate the revenue share during the forecast period, primarily due to the introduction of new treatment options in this region. Additionally, increased healthcare expenditures and the availability of treatment choices are expected to boost revenue growth. Rising awareness about the disease in North America also contributes to the market's growth.

Fastest Growing Region Asia Pacific is projected to exhibit significant revenue growth with a notable CAGR during the forecast period. This growth can be attributed to the considerable increase in the population in countries like China and India. Moreover, the presence of generic manufacturers and the expansion of healthcare facilities in the region will drive market growth.

Key Market Trends and Innovations

A multicenter, randomized, double-blind, and placebo-controlled Phase II trial is underway since February 2022, focusing on patients with panic disorder, with or without specified co-morbidities. The study aims to assess the safety and effectiveness of HB-1 compared to a placebo in adult patients with panic disorder.
From June to December 2021, a double-blind, randomized, and placebo-controlled Phase II and Phase III trial was conducted to evaluate Xenon Inhalation for treating patients with panic disorder. The results suggest that Xenon is a viable therapeutic option, and its anti-panic effects can last for at least six months after active treatment.

Competitive Landscape Organic and Inorganic Strategies:

Since April 2019, McMaster University and Purdue Pharma, Canada, have collaborated to conduct a Phase IV clinical trial investigation on Methylphenidate Hydrochloride Controlled Release Capsules in adult ADHD, with and without an anxiety disorder.
In March 2019, the U.S. Food and Drug Administration (FDA) approved Spravato (esketamine) nasal spray for the treatment of depression in individuals who have not responded to other antidepressants when used in conjunction with an oral antidepressant.

Explore Trending Reports:

Chitosan Market-https://www.globenewswire.com/news-release/2019/10/08/1926590/0/en/Chitosan-Market-To-Reach-USD-1-664-6-Million-By-2026-Reports-And-Data.html

Acetic Acid Market-https://www.globenewswire.com/news-release/2020/01/07/1967588/0/en/Acetic-Acid-Market-To-Reach-USD-21-65-Billion-By-2027-Reports-And-Data.html

Biotech Ingredients Market-https://www.globenewswire.com/news-release/2020/05/20/2036288/0/en/Biotech-Ingredients-Market-To-Reach-USD-3-03-Billion-By-2027-Reports-and-Data.html

Tertiary Amines Market-https://www.globenewswire.com/en/news-release/2021/03/04/2186779/0/en/Tertiary-Amines-Market-To-Be-Worth-USD-6-72-Billion-in-2028-CAGR-of-5-6-Reports-And-Data.html

Request a customization of the report: https://www.reportsanddata.com/request-customization-form/5166

Thank you for reading our report. To know more about the customization or any query about the report contents, please connect with us and our team will ensure the report is tailored to meet your requirements.

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behaviour shifts across demographics, across industries, and help clients to make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Products, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

John W

(Head of Business Development)

Reports and Data | Web: www.reportsanddata.com

Direct Line: +1-212-710-1370

E-mail: sales@reportsanddata.com

Blogs | Press Release | Industry News | Our competencies

Browse More Upcoming Reports @ https://www.reportsanddata.com/upcoming-reports